Statements (164)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:accessories |
gptkb:medical_devices
COVID-19 vaccines globally |
| gptkbp:accreditation |
gptkb:ISO_9001
|
| gptkbp:acquired |
gptkb:China_National_Pharmaceutical_Group
China National Pharmaceutical Group in 2016 |
| gptkbp:acquisition |
China National Pharmaceutical Group in 2016
various pharmaceutical firms |
| gptkbp:allies |
international pharmaceutical companies
|
| gptkbp:ceo |
Liang Zhiqiang
|
| gptkbp:clinical_trial |
COVID-19 vaccine trials
vaccine safety studies vaccine efficacy studies multiple vaccine candidates vaccine distribution studies |
| gptkbp:collaborates_with |
gptkb:World_Health_Organization
various international health organizations |
| gptkbp:collaboration |
international health organizations
|
| gptkbp:collaborations |
academic institutions
|
| gptkbp:community_engagement |
health education programs
|
| gptkbp:community_impact |
public health initiatives
|
| gptkbp:community_outreach |
health awareness campaigns
|
| gptkbp:distribution |
vaccines and medicines
|
| gptkbp:distribution_channels |
Asia and Africa
|
| gptkbp:employees |
over 100,000
|
| gptkbp:employs |
over 30,000 people
over 100,000 people |
| gptkbp:financial_performance |
strong growth
|
| gptkbp:financial_support |
healthcare projects
|
| gptkbp:founded |
gptkb:2003
|
| gptkbp:global_presence |
over 100 countries
|
| gptkbp:has_part |
gptkb:health_services
gptkb:Sinopharm_Bio gptkb:Sinopharm_Capital gptkb:Sinopharm_Holding gptkb:Sinopharm_International_Corporation gptkb:Sinopharm_Investment gptkb:Sinopharm_Logistics gptkb:Sinopharm_Research gptkb:Sinopharm_Technology gptkb:supply_chain_management gptkb:medical_devices OTC drugs clinical trials community outreach programs prescription drugs public health initiatives distribution network generic drugs logistics services nutritional products vaccination programs international partnerships manufacturing plants sustainability programs biologics employee training programs customer service teams diagnostic products research collaborations research and development facilities pharmaceutical distribution human resources department corporate social responsibility initiatives quality control systems clinical research services regulatory affairs department environmental health and safety department marketing and sales teams legal affairs department IT services department Sinopharm Consulting Sinopharm Distribution Sinopharm Education Sinopharm Health financial services department Sinopharm Academy Sinopharm Alliances Sinopharm Clinical Trials Sinopharm Collaborations Sinopharm Community Engagement Sinopharm Corporate Social Responsibility Sinopharm Customer Service Sinopharm Development Sinopharm Industrial Sinopharm Innovation Sinopharm Manufacturing Sinopharm Market Research Sinopharm Marketing Sinopharm Networks Sinopharm Outreach Sinopharm Partnerships Sinopharm Pharmaceutical Sinopharm Product Development Sinopharm Public Relations Sinopharm Quality Control Sinopharm Regulatory Affairs Sinopharm Research Center Sinopharm Research Institute Sinopharm Sales Sinopharm Services Sinopharm Solutions Sinopharm Supply Chain Sinopharm Technology Transfer Sinopharm Trading Sinopharm Training |
| gptkbp:has_product |
antibiotics
biopharmaceuticals influenza vaccines Sinopharm COVID-19 vaccine hepatitis vaccines |
| gptkbp:headquarters |
gptkb:Beijing,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sinopharm Group
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
biologics
vaccine technology |
| gptkbp:investment |
biotechnology companies
healthcare infrastructure |
| gptkbp:is_displayed_in |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:is_known_for |
COVID-19 vaccine development
|
| gptkbp:is_part_of |
gptkb:China_National_Pharmaceutical_Group
|
| gptkbp:is_vulnerable_to |
Sinopharm BIBP vaccine
|
| gptkbp:market |
gptkb:China
pharmaceutical trends |
| gptkbp:market_cap |
over 200 billion CNY
over $50 billion (2021) |
| gptkbp:market_launch |
new vaccines
|
| gptkbp:marketing_strategy |
expansion in emerging markets
|
| gptkbp:offers |
vaccines
COVID-19 vaccines |
| gptkbp:operates_in |
gptkb:pharmaceuticals
gptkb:medical_devices vaccine development pharmaceutical distribution |
| gptkbp:parent_company |
gptkb:China_National_Pharmaceutical_Group
|
| gptkbp:part_of |
gptkb:China_National_Pharmaceutical_Group
|
| gptkbp:partnership |
gptkb:World_Health_Organization
local governments non-profit organizations research institutions government health agencies |
| gptkbp:philanthropy |
healthcare initiatives
|
| gptkbp:product |
new therapeutics
|
| gptkbp:product_line |
generic drugs
|
| gptkbp:products |
vaccines
|
| gptkbp:regulatory_compliance |
gptkb:various_countries
international standards |
| gptkbp:research_and_development |
biopharmaceuticals
|
| gptkbp:research_focus |
infectious diseases
|
| gptkbp:research_interest |
vaccine development.
|
| gptkbp:revenue |
over 100 billion CNY
over $30 billion (2020) |
| gptkbp:social_responsibility |
healthcare access initiatives
|
| gptkbp:stock_exchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:subsidiaries |
gptkb:Sinopharm_Holding
|
| gptkbp:subsidiary |
gptkb:Sinopharm_International_Corporation
Sinopharm Holding Co., Ltd. Sinopharm Vaccine Sinopharm Weiqida Pharmaceutical Co., Ltd. |
| gptkbp:supply_chain |
logistics solutions
pharmaceutical distribution |
| gptkbp:sustainability |
environmental initiatives
|
| gptkbp:bfsParent |
gptkb:China_National_Pharmaceutical_Group_Corporation
|
| gptkbp:bfsLayer |
5
|